Aklief can produce visible improvement in as little as two weeks on the face and four weeks on the body. Full results, however, take closer to 12 weeks of consistent nightly use. Most people notice their skin getting worse before it gets better, which is a normal part of the process and not a sign the medication isn’t working.
The First Two Weeks: Early Signs on the Face
In two large clinical trials involving over 2,400 patients with moderate acne, Aklief significantly reduced inflammatory lesions (red, swollen pimples and pustules) on the face compared to placebo as early as week two. That doesn’t mean your skin will look dramatically different at the two-week mark, but measurable changes are already happening beneath the surface. Cell turnover is speeding up, pores are beginning to unclog, and the cycle of new breakouts starts to slow.
Body acne responds a bit more slowly. On the chest, shoulders, and back, significant reductions in lesions showed up around week four in the same trials. The skin on your trunk is thicker than facial skin, so the active ingredient takes longer to do its work there.
What 12-Week Results Actually Look Like
The benchmark in clinical trials was 12 weeks of daily use. At that point, researchers measured how many patients achieved “clear” or “almost clear” skin with at least a two-grade improvement from where they started. The results varied between the two Phase 3 studies:
- Facial acne: 29% to 42% of Aklief users reached clear or almost-clear skin at 12 weeks, compared to 20% to 26% using the vehicle cream alone.
- Trunk acne: 36% to 43% of Aklief users hit the same benchmark on the body, compared to 25% to 30% with the vehicle.
Those numbers might seem modest at first glance, but “clear or almost clear” is a high bar. Many more patients saw meaningful improvement without fully crossing that threshold. The gap between Aklief and the vehicle cream also confirms the drug is doing real work beyond what a basic skincare routine would accomplish on its own. And results continue to improve past the 12-week mark with continued use.
The Irritation Phase Is Predictable
If your skin feels worse during the first few weeks, you’re in good company. Redness, scaling, dryness, and stinging or burning are common early reactions, and the FDA labeling notes they peak at specific, predictable times: around week one for the face and between weeks two and four for the trunk. After that peak, severity decreases with continued use.
This adjustment period, sometimes called retinization, is your skin adapting to faster cell turnover. Old clogged pores get pushed to the surface more quickly, which can look and feel like a breakout. It’s tempting to quit during this phase, but the irritation is temporary. In a year-long safety study of 453 patients, only 3.5% discontinued due to side effects, and the safety profile at 52 weeks looked the same as it did during short-term use. The most common issues over the long haul were mild: sunburn (6%), itching at the application site (5.1%), and irritation (4.9%).
How to Apply It Without Slowing Results
Because early irritation is the main reason people either quit or start skipping nights, buffering with moisturizer is a common strategy. Recent research on how moisturizer interacts with retinoids offers a useful rule of thumb: applying moisturizer either before or after the retinoid (an “open sandwich”) preserves the medication’s activity. But layering moisturizer both before and after (a “full sandwich”) cuts its bioactivity by roughly threefold due to dilution and reduced skin penetration.
So if irritation is bothering you, apply a gentle moisturizer first and let it absorb, then apply Aklief on top. Or apply Aklief first and follow with moisturizer. Either order works without meaningfully reducing effectiveness. Just avoid doing both.
Why Aklief Works Differently Than Older Retinoids
Aklief’s active ingredient, trifarotene, is classified as a fourth-generation retinoid. What sets it apart is selectivity. Older topical retinoids activate multiple types of retinoic acid receptors in the skin, which gets the job done but also triggers more widespread irritation. Trifarotene targets only one specific receptor subtype, the one most abundant in skin. This selectivity was designed to maintain the acne-clearing power of earlier retinoids while producing fewer side effects, and the clinical data supports that tradeoff.
This is also why Aklief is the first retinoid specifically FDA-approved for treating acne on the trunk, not just the face. The body has a large surface area to cover, and a drug that causes less irritation across all that skin is a practical advantage for people dealing with chest or back breakouts.
Realistic Expectations by Month
Here’s a rough timeline based on the clinical trial data and FDA labeling:
- Weeks 1 to 4: Skin irritation peaks. You may experience new breakouts, dryness, and redness. Measurable improvement in facial acne begins around week two, though it may not be visible to you yet.
- Weeks 4 to 8: Irritation starts to fade. Body acne begins responding. Many people notice fewer new breakouts forming, even if older blemishes are still healing.
- Weeks 8 to 12: The clearest improvements become visible. This is the window where clinical trials measured their primary outcomes, and roughly 29% to 42% of users achieve clear or almost-clear facial skin.
- Beyond 12 weeks: Continued use brings continued improvement. The year-long safety study confirmed that long-term daily application is well tolerated, with no new safety concerns emerging over 52 weeks.
Consistency matters more than anything else with Aklief. Skipping nights to avoid irritation is understandable, but it delays results. If the irritation is genuinely hard to tolerate, buffering with a single layer of moisturizer is a better strategy than reducing frequency, since it protects your skin without meaningfully weakening the medication.